The first case of the novel coronavirus was reported on 31 December 2019. While a sure shot treatment is still not known, already existing drugs such as Remdesivir, Lopinavir, Ritonavir, Chloroquine and its derivative Hydroxychloroquine have come up in several clinical trials as possible treatments for COVID-19. These are what's called 'repurposed drugs,' drugs already existing for some treatments, being 'repurposed' for coronavirus.
ICMR’s U-Turn on Hydroxychloroquine
Among these, Hydroxychloroquine specifically is being endorsed as a potential treatment, so much so that ICMR has already approved on 22 March, its use as prophylactic for the high-risk population such as the healthcare workers and those directly exposed to COVID-19 patients.
After nearly a month of its approval as a prophylactic, in a press conference on 18 April, the head of ICMR's epidemiology, Dr Raman Gangakhedkar, said that an observational study on the impact of hydroxychloroquine (HCQ) as a prophylactic and therapeutic drug was being conducted.
Global Curiosity Around The Drug
Deepa Agashe, Scientist at National Centre For Biological Sciences, B'luru says, “A lot of people have this big question in their mind, ‘What evidence do we have to prove that Hydroxychloroquine is a good prophylactic or medicine to treat COVID-19?’All medicine that you see in the market is calibrated carefully for whatever disease it is supposed to fix.”
The reason we don't know that yet is because of the availability of only limited scientific studies and results from clinical trials conducted on a small sample of the population. While it's true that hydroxychloroquine is not very expensive and is readily available, one big concern remains that it has not shown impressive results among critically ill patients who are receiving several other medications and have organ failure.
One study that did show results for those with mild symptoms, seemed to indicate that taken with antibiotic azithromycin, it brought down the viral load drastically. But there were major problems with the study.
The Sudden Rise in Demand
Despite not having enough research and studies backing hydroxychloroquine as a cure, the demand for the drug has swelled in the past months as unverified claims around its usage continued to flood social media platforms. The Quint has debunked several such claims.
“India produces 70 percent of the entire world's Hydroxychloroquine. We use it as an anti-malaria drug, for treatment of Lupus; but, out of the 250 crore tablets produced in India every year, only 1 percent is sold in India and the rest of it is exported,” said Aniket Sule from Homi Bhabha Centre for Science Education.
India imposed and later lifted a ban on the export of the drug is now supplying the anti-malarial to 55 countries including the United States, Brazil, Israel, Nepal, Bhutan, Sri Lanka and others.
Shortage of Drug For Other Medical Conditions
This poses another serious problem. There is a shortage of the drug for patients who need it for other conditions, like rheumatoid arthritis and malaria. There is a global curiosity around the drug without any significant studies backing it.
While the drug has shown some potential, it is extremely important to understand that hydroxychloroquine as a cure for COVID-19 is not 100 per cent certain. Mass hysteria around the usage of drug not only poses serious health problems for the consumer it also results in a short of the life-saving drug for people who actually need it.
Also Read: Just How Accurate are Coronavirus Tests?
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)